HK1043115A1 - 矩阵金属蛋白酶反异羟肟酸盐抑制剂 - Google Patents

矩阵金属蛋白酶反异羟肟酸盐抑制剂 Download PDF

Info

Publication number
HK1043115A1
HK1043115A1 HK02102947.8A HK02102947A HK1043115A1 HK 1043115 A1 HK1043115 A1 HK 1043115A1 HK 02102947 A HK02102947 A HK 02102947A HK 1043115 A1 HK1043115 A1 HK 1043115A1
Authority
HK
Hong Kong
Prior art keywords
matrix metalloproteinases
hydroxamate inhibitors
reverse hydroxamate
inhibitors
reverse
Prior art date
Application number
HK02102947.8A
Other languages
English (en)
Chinese (zh)
Inventor
L. Curtin Michael
Gurnee Dai Yujia
K. Davidsen Steven
R. Heyman Howard
H. Holmes James
R. Michaelides Michael
H. Steinman Douglas
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HK1043115A1 publication Critical patent/HK1043115A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK02102947.8A 1999-01-27 2000-01-27 矩阵金属蛋白酶反异羟肟酸盐抑制剂 HK1043115A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27
US09/239,087 1999-01-27
PCT/US2000/002038 WO2000044739A1 (en) 1999-01-27 2000-01-27 Reverse hydroxamate inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
HK1043115A1 true HK1043115A1 (zh) 2002-09-06

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102947.8A HK1043115A1 (zh) 1999-01-27 2000-01-27 矩阵金属蛋白酶反异羟肟酸盐抑制剂

Country Status (28)

Country Link
US (1) US20020007060A1 (https=)
EP (1) EP1147101B1 (https=)
JP (1) JP4718686B2 (https=)
KR (1) KR100748010B1 (https=)
CN (1) CN1222519C (https=)
AR (1) AR029329A1 (https=)
AT (1) ATE228122T1 (https=)
AU (1) AU764383B2 (https=)
BG (1) BG105782A (https=)
BR (1) BR0007278A (https=)
CA (1) CA2358951C (https=)
CO (1) CO5150194A1 (https=)
CZ (1) CZ20012591A3 (https=)
DE (1) DE60000819T2 (https=)
DK (1) DK1147101T3 (https=)
ES (1) ES2187443T3 (https=)
HK (1) HK1043115A1 (https=)
HU (1) HUP0105477A2 (https=)
IL (1) IL143713A0 (https=)
NO (1) NO20013669L (https=)
NZ (1) NZ512372A (https=)
PL (1) PL349771A1 (https=)
PT (1) PT1147101E (https=)
SK (1) SK10582001A3 (https=)
TR (1) TR200102159T2 (https=)
TW (1) TWI225486B (https=)
WO (1) WO2000044739A1 (https=)
ZA (1) ZA200104979B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO2003063762A2 (en) * 2001-01-12 2003-08-07 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
DE60230781D1 (en) 2001-09-07 2009-02-26 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren

Also Published As

Publication number Publication date
CZ20012591A3 (cs) 2001-12-12
JP4718686B2 (ja) 2011-07-06
PT1147101E (pt) 2003-04-30
ZA200104979B (en) 2002-09-18
ES2187443T3 (es) 2003-06-16
TWI225486B (en) 2004-12-21
JP2002535398A (ja) 2002-10-22
IL143713A0 (en) 2002-04-21
EP1147101B1 (en) 2002-11-20
NO20013669D0 (no) 2001-07-26
US20020007060A1 (en) 2002-01-17
BG105782A (en) 2002-04-30
CO5150194A1 (es) 2002-04-29
AU764383B2 (en) 2003-08-14
DE60000819D1 (de) 2003-01-02
HUP0105477A2 (hu) 2002-05-29
TR200102159T2 (tr) 2001-12-21
WO2000044739A1 (en) 2000-08-03
CN1339032A (zh) 2002-03-06
CN1222519C (zh) 2005-10-12
BR0007278A (pt) 2001-11-27
DE60000819T2 (de) 2003-09-04
ATE228122T1 (de) 2002-12-15
SK10582001A3 (sk) 2001-12-03
DK1147101T3 (da) 2003-03-10
KR100748010B1 (ko) 2007-08-09
CA2358951C (en) 2009-10-20
NZ512372A (en) 2003-01-31
AR029329A1 (es) 2003-06-25
AU2739100A (en) 2000-08-18
KR20010101709A (ko) 2001-11-14
EP1147101A1 (en) 2001-10-24
NO20013669L (no) 2001-09-27
PL349771A1 (en) 2002-09-09
CA2358951A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
IL133369A0 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
PL350193A1 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
GB9912961D0 (en) Metalloprotease inhibitors
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
AU2108601A (en) Salicylamides as serine protease inhibitors
PL349025A1 (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
NO994103D0 (no) Reverse hydroksamatderivater som metallproteaseinhibitorer
AU5634999A (en) Hydroxamic acid derivatives as proteinase inhibitors
AU6764400A (en) Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
AU4433700A (en) Prolyl endopeptidase inhibitor
AU2001265182A1 (en) Inhibitors of matrix metalloproteinases
HK1043115A1 (zh) 矩阵金属蛋白酶反异羟肟酸盐抑制剂
AU2001241498A1 (en) Matrix metalloproteinase inhibitors and uses thereof
PL357084A1 (en) Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
IL151250A0 (en) Difluorobutyric acid metalloprotease inhibitors
AU2001295966A1 (en) Cell damage inhibitor
AU2001232113A1 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
IL132315A0 (en) Compositions comprising oxophosphonate-based metalloproteinase inhibitors
SI1147101T1 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
AU2001271068A1 (en) Matrix metalloprotease inhibitors
AU4133800A (en) Inhibition of endopeptidase by cystatins
AU2002235225A1 (en) Matrix metalloproteinase inhibitors
AU6843598A (en) Metalloproteinase inhibitors
AU5709500A (en) Serine protease inhibitor
HK1060122A (en) Metalloproteinase inhibitors